These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 23447136)

  • 21. Inflammatory Orbitopathy Associated With Ipilimumab.
    Sheldon CA; Kharlip J; Tamhankar MA
    Ophthalmic Plast Reconstr Surg; 2017; 33(3S Suppl 1):S155-S158. PubMed ID: 26068559
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Treatment and side effect management of CTLA-4 antibody therapy in metastatic melanoma.
    Kähler KC; Hauschild A
    J Dtsch Dermatol Ges; 2011 Apr; 9(4):277-86. PubMed ID: 21083648
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Ipilimumab in the treatment of melanoma.
    Trinh VA; Hwu WJ
    Expert Opin Biol Ther; 2012 Jun; 12(6):773-82. PubMed ID: 22500861
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Ipilimumab: a guide to its use in advanced melanoma.
    Lyseng-Williamson KA; Sanford M
    Am J Clin Dermatol; 2012 Oct; 13(5):349-54. PubMed ID: 22849352
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Long-lasting responses under treatment with ipilimumab: an argument against maintenance therapy?
    Dick J; Enk A; Hassel JC
    Dermatology; 2015; 230(1):8-10. PubMed ID: 25531526
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Neutropenia in a patient treated with ipilimumab (anti-CTLA-4 antibody).
    Akhtari M; Waller EK; Jaye DL; Lawson DH; Ibrahim R; Papadopoulos NE; Arellano ML
    J Immunother; 2009 Apr; 32(3):322-4. PubMed ID: 19242368
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Management of immune-related adverse events and kinetics of response with ipilimumab.
    Weber JS; Kähler KC; Hauschild A
    J Clin Oncol; 2012 Jul; 30(21):2691-7. PubMed ID: 22614989
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Review: anti-CTLA-4 antibody ipilimumab: case studies of clinical response and immune-related adverse events.
    Weber J
    Oncologist; 2007 Jul; 12(7):864-72. PubMed ID: 17673617
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Late-onset paraplegia after complete response to two cycles of ipilimumab for metastatic melanoma.
    O'Kane GM; Lyons TG; Colleran GC; Ahmad MW; Alken S; Kavanagh EC; Fitzpatrick D; Murray B; Kelly CM
    Oncol Res Treat; 2014; 37(12):757-60. PubMed ID: 25531722
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Long-term follow-up of ipilimumab-induced hypophysitis, a common adverse event of the anti-CTLA-4 antibody in melanoma.
    Albarel F; Gaudy C; Castinetti F; Carré T; Morange I; Conte-Devolx B; Grob JJ; Brue T
    Eur J Endocrinol; 2015 Feb; 172(2):195-204. PubMed ID: 25416723
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Ipilimumab: a novel immunomodulating therapy causing autoimmune hypophysitis: a case report and review.
    Juszczak A; Gupta A; Karavitaki N; Middleton MR; Grossman AB
    Eur J Endocrinol; 2012 Jul; 167(1):1-5. PubMed ID: 22495490
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Guillain-Barré Syndrome Triggered by Immune Checkpoint Inhibitors: A Case Report and Literature Review.
    Supakornnumporn S; Katirji B
    J Clin Neuromuscul Dis; 2017 Dec; 19(2):80-83. PubMed ID: 29189553
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Ipilimumab in melanoma with limited brain metastases treated with stereotactic radiosurgery.
    Mathew M; Tam M; Ott PA; Pavlick AC; Rush SC; Donahue BR; Golfinos JG; Parker EC; Huang PP; Narayana A
    Melanoma Res; 2013 Jun; 23(3):191-5. PubMed ID: 23462208
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Safety and clinical activity of ipilimumab in melanoma patients with brain metastases: retrospective analysis of data from a phase 2 trial.
    Weber JS; Amin A; Minor D; Siegel J; Berman D; O'Day SJ
    Melanoma Res; 2011 Dec; 21(6):530-4. PubMed ID: 22051508
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Therapeutic monoclonal antibodies in human breast milk: a case study.
    Ross E; Robinson SE; Amato C; McMillan C; Westcott J; Wolf T; Robinson WA
    Melanoma Res; 2014 Apr; 24(2):177-80. PubMed ID: 24476799
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Ipilimumab-induced acute severe colitis treated by infliximab.
    Pagès C; Gornet JM; Monsel G; Allez M; Bertheau P; Bagot M; Lebbé C; Viguier M
    Melanoma Res; 2013 Jun; 23(3):227-30. PubMed ID: 23458760
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A severe case of ipilimumab-induced guillain-barré syndrome revealed by an occlusive enteric neuropathy: a differential diagnosis for ipilimumab-induced colitis.
    Gaudy-Marqueste C; Monestier S; Franques J; Cantais E; Richard MA; Grob JJ
    J Immunother; 2013 Jan; 36(1):77-8. PubMed ID: 23211620
    [TBL] [Abstract][Full Text] [Related]  

  • 38. New-onset mediastinal and central nervous system sarcoidosis in a patient with metastatic melanoma undergoing CTLA4 monoclonal antibody treatment.
    Murphy KP; Kennedy MP; Barry JE; O'Regan KN; Power DG
    Oncol Res Treat; 2014; 37(6):351-3. PubMed ID: 24903767
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Radiologic aspects of immune-related tumor response criteria and patterns of immune-related adverse events in patients undergoing ipilimumab therapy.
    O'Regan KN; Jagannathan JP; Ramaiya N; Hodi FS
    AJR Am J Roentgenol; 2011 Aug; 197(2):W241-6. PubMed ID: 21785048
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A randomized, double-blind, placebo-controlled, phase II study comparing the tolerability and efficacy of ipilimumab administered with or without prophylactic budesonide in patients with unresectable stage III or IV melanoma.
    Weber J; Thompson JA; Hamid O; Minor D; Amin A; Ron I; Ridolfi R; Assi H; Maraveyas A; Berman D; Siegel J; O'Day SJ
    Clin Cancer Res; 2009 Sep; 15(17):5591-8. PubMed ID: 19671877
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.